What is HC Wainwright’s Estimate for TPST FY2025 Earnings?

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Research analysts at HC Wainwright upped their FY2025 earnings estimates for shares of Tempest Therapeutics in a research report issued on Thursday, January 22nd. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($6.10) per share for the year, up from their prior estimate of ($12.78). The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q4 2025 earnings at ($0.62) EPS, FY2026 earnings at ($2.76) EPS, FY2027 earnings at ($2.28) EPS and FY2028 earnings at ($2.13) EPS.

Other equities analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempest Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised Tempest Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 11th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Tempest Therapeutics presently has a consensus rating of “Reduce” and a consensus target price of $12.50.

Tempest Therapeutics Trading Down 2.7%

Shares of TPST stock opened at $2.90 on Monday. The firm has a market capitalization of $14.30 million, a PE ratio of -0.29 and a beta of -2.43. The firm has a fifty day simple moving average of $3.18 and a two-hundred day simple moving average of $7.21. Tempest Therapeutics has a 12 month low of $2.40 and a 12 month high of $12.74.

Shares of Tempest Therapeutics are going to split on the morning of Friday, January 30th. The 2-1 split was recently announced. The newly created shares will be distributed to shareholders after the closing bell on Thursday, January 29th.

Tempest Therapeutics (NASDAQ:TPST) last issued its earnings results on Wednesday, November 5th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.27) by $2.48.

Institutional Investors Weigh In On Tempest Therapeutics

A hedge fund recently raised its stake in Tempest Therapeutics stock. Vanguard Group Inc. raised its position in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162,560 shares of the company’s stock after buying an additional 27,952 shares during the quarter. Vanguard Group Inc. owned about 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent reporting period. 22.52% of the stock is currently owned by institutional investors and hedge funds.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.